RxDoctor Payments Data

Evan Dellon

Gastroenterology · Chapel Hill, NCNPI 1609098623

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $364,886 of the $431,027 with a category attached, or 84.7%. 25 manufacturers reported payments, led by Regeneron at 26.4% of the total. Among gastroenterology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$431,027in general payments, 2019–2025

Across 250 payments — averaging $1724.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$114K
  • Takeda Pharmaceuticals U.S.A., Inc.$49K
  • Sanofi$47K
  • Sanofi-aventis U.S. LLC$42K
  • AstraZeneca$38K
  • E.r. Squibb & Sons, L.L.C.$25K
  • plus $116K from 19 others
$10,873,768in research payments, 2019–2025

Across 647 payments — averaging $16,806 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$5.4M
  • Regeneron$2.1M
  • AstraZeneca$1.3M
  • Bristol Myers Squibb$817K
  • Takeda Pharmaceuticals U.S.A., Inc.$337K
  • Sanofi$272K
  • plus $597K from 6 others

What the payments were for

  • Consulting fees$364,88685%
  • Speaking & faculty fees$48,25111%
  • Grants$3,0001%
  • Travel & lodging$12,3183%
  • Food & beverage$2,0590%
  • Education$5130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431,027 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$9,242
Medicare patients
54
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab27$146,954
Dupixent SyringeDupilumab12$105,699
Fluticasone Propionate HfaFluticasone Propionate25$14,349
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine21$818
Promethazine Hcl27$544
Omeprazole45$513
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$387
Dicyclomine Hcl16$280
Venlafaxine Hcl ErVenlafaxine Hcl14$224
Pantoprazole Sodium14$107

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →